QDEL vs. NEOG, CLDX, NTLA, MYGN, LNTH, HIMS, OLK, LTH, IOVA, and GH
Should you be buying QuidelOrtho stock or one of its competitors? The main competitors of QuidelOrtho include Neogen (NEOG), Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Lantheus (LNTH), Hims & Hers Health (HIMS), Olink Holding AB (publ) (OLK), Life Time Group (LTH), Iovance Biotherapeutics (IOVA), and Guardant Health (GH). These companies are all part of the "medical" sector.
Neogen (NASDAQ:NEOG) and QuidelOrtho (NASDAQ:QDEL) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability, community ranking and analyst recommendations.
Neogen has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, QuidelOrtho has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500.
Neogen currently has a consensus price target of $22.50, indicating a potential upside of 66.17%. QuidelOrtho has a consensus price target of $59.00, indicating a potential upside of 37.79%. Given QuidelOrtho's stronger consensus rating and higher possible upside, equities analysts clearly believe Neogen is more favorable than QuidelOrtho.
QuidelOrtho received 110 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 67.28% of users gave QuidelOrtho an outperform vote while only 57.19% of users gave Neogen an outperform vote.
96.7% of Neogen shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 0.7% of Neogen shares are owned by insiders. Comparatively, 1.0% of QuidelOrtho shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
QuidelOrtho has higher revenue and earnings than Neogen. QuidelOrtho is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.
In the previous week, QuidelOrtho had 14 more articles in the media than Neogen. MarketBeat recorded 16 mentions for QuidelOrtho and 2 mentions for Neogen. QuidelOrtho's average media sentiment score of 0.59 beat Neogen's score of 0.07 indicating that Neogen is being referred to more favorably in the media.
Neogen has a net margin of 0.17% compared to Neogen's net margin of -61.65%. Neogen's return on equity of 3.96% beat QuidelOrtho's return on equity.
Summary
Neogen and QuidelOrtho tied by winning 9 of the 18 factors compared between the two stocks.
Get QuidelOrtho News Delivered to You Automatically
Sign up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QDEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
QuidelOrtho Competitors List
Related Companies and Tools
